Nedsat leverfunktion - Efter subkutan injektion af en enkel dosis fondaparinux til patienter med moderat nedsat leverfunktion (Child- Pugh kategori B) var total (bundet og ubundet) Cmax og AUC reduceret med henholdsvis 22% og 39% sammenlignet med patienter med normal leverfunktion.
Hepatic impairment - Following a single, subcutaneous dose of fondaparinux in subjects with moderate hepatic impairment (Child-Pugh Category B), total (i. e., bound and unbound) Cmax and AUC were decreased by 22% and 39%, respectively, as compared to subjects with normal liver function.